The effect of heparin on tissue factor and tissue factor pathway inhibitor in patients with acute myocardial infarction

International Journal of Cardiology

Volumn 75, Issue 2-3, 2000, Pages 267-274

  Yamamoto, Nobuyasu ^a   Ogawa, Hisao ^b   Oshima, Shuichi ^a   Soejima, Hirofumi ^b   Fujii, Hiromi ^c   Misumi, Kenji ^b   Takazoe, Keiji ^b   Mizuno, Yuji ^b   Noda, Katsuo ^a   Saito, Taro ^a   Tsuji, Ichiro ^e   Kumeda, Kousuke ^e   Nakamura, Shin ^d   Yasue, Hirofumi ^b  

^a Kumamoto Central Hospital   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Kumamoto Kinoh Hospital   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Coagulation; Heparin; Myocardial infarction; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; NITRATE; PLASMINOGEN ACTIVATOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THORAX PAIN; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOPLASTIN;

EID: 0034664921     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00345-4     Document Type: Article

References (39)

1. Tissue factor and hemostasis
2. The structural biology of expression and function of tissue factor
3. The role of tissue factor in the production of thrombin
4. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
5. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
6. The lipoprotein-associated coagulation inhibitor
7. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation
8. Elevated tissue factor pathway inhibitor circulating levels in ischemic heart disease patients
9. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
10. Plasma tissue factor: Its sensitive assay and characterization
11. Monoclonal antibodies to human tissue factor
12. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma
13. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): Comparison with human TFPI
14. One-way classifications: Analysis of variance
15. Quantification of coronary arterial narrowing at necropsy in acute transmural myocardial infarction: Analysis and comparison of findings in 27 patients and 22 controls
16. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
17. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris
18. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes
19. Increased monocyte tissue factor expression in coronary disease
20. Effect of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction
21. Increased plasma tissue factor levels in acute myocardial infarction
22. Comparison of plasma tissue factor levels in unstable and stable angina pectoris
23. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
24. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction
25. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin
26. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris
27. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity
28. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
29. Tissue-factor antigen and activity in human coronary atherosclerotic plaques
30. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina
31. Expression of functional tissue factor on small vesicle of lipopolysaccharide-stimulated human vascular endothelial cells
32. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
33. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques
34. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor
35. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
36. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI)
37. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
38. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor
39. Release of extrinsic pathway inhibitor after heparin injection: Increased response in cancer patients